1. A method of measurement in vitro of purine biosynthesis de novo in human circulating blood lymphocytes is proposed. The rate of early reac tions of purine biosynthesis de novo was deter mined by the incorporation of [ I4 C]formate into JVformyl glycinamide ribonucleotide when the subse quent reactions of the metabolic pathway were completely inhibited by the antibiotic azaserine.
Introduction
The measurement of purine biosynthesis de novo in isolated cells has been studied in gout. An insensitive method has been used in human leucocytes (Diamond, Friedland, Halberstam & Kaplan, 1969; Chang, Fam, Little & Malkin, 1974) , using [ 14 C]glycine and measuring its incor poration into adenine and guanine residues of DNA and 'insoluble' RNA. Alternatively, the first steps of purine biosynthesis de novo can be measured with either [ 14 C]formate or f 14 C]glycine as precursor of the JV-formyl glycinamide ribo nucleotide and azaserine, which irreversibly inhibits the pathway at this nucleotide level (Bennett, Schabel & Skipper, 1956; French, Dawid, Day & Buchanan, 1963) . This method has been used in fibroblasts derived from skin biopsy (Kelley & Wyngaarden, 1970) and leukaemic and ascites tumour cells in culture (Henderson, 1962) . We have applied this technique directly to human circulating blood lymphocytes without cell culture.
Materials and methods

Subjects
Three groups of subjects were studied. Informed consent for drawing blood samples was obtained from each subject and the research was carried out according to the Declaration of Helsinki. Group 1 consisted of 20 healthy volunteer blood donors (12 males and eight females) aged from 20 to 62 years. Plasma uric acid concentration measured by the standard Auto-analyzer method was 0-32 + 0-02 mmol/1 (mean ± SEM). In group 2 (18 males and six females) primary gout was diagnosed by the usual clinical criteria (Wyngaarden & Kelley, 1972) . Arthritis was classified in three stages: (a) resolving acute arthritis, nine patients; (b) chronic arthritis, nine patients including one patient with uraemia; (c) destructive arthritis with extraarticular tophi (clinical joint deformity with limited movement and X-ray evidence), six patients includ ing three patients with uraemia. In these patients the diagnosis of primary gout was made according to the following criteria: knowledge of arthritis and hyperuricaemia 7-30 years before the onset of uraemia. Familial gout was noted in five patients of two families. Eleven patients (group 2B) were treated with allopurinol (29-48 ßmol day -1 kg"'; 4-0-6-5 mg day -1 kg -1 )· The plasma uric acid con centration (mean + SEM) was 0-39 ± 0-04 mmol/1, whereas in the remaining patients (group 2A) this concentration was 0-55 ± 0-03 mmol/1. One patient was studied before and during allopurinol therapy. Twenty-two patients in group 3 consisted of 10 males and 12 females with renal failure and secondary hyperuricaemia without any clinical criteria of gout. Eight (group 3B) were treated with allopurinol (29-48 μτηοΐ day' 1 kg -1 ; 4·0-6·5 mg day" 1 kg -1 ). Their plasma uric acid concentration was 0-47 + 0-04 mmol/1 whereas in the remaining patients (group 3 A) this concentration was 0-64 + 0-03 mmol/1. The aetiology of their renal failure was: chronic glomerulonephritis (five cases in group 3A, two cases in group 3B); interstitial nephritis (five case in group 3A, four cases in group 3B); acute glomerulonephritis (one case in group 3A); nephrosclerosis (three cases in group 3A, one case in group 3B); polycystic kidneys (one case in group 3B).
Preparation and incubation of lymphocytes
Fasting venous blood (40 ml) was collected in plastic tubes containing 2-5 mg of heparin (Liquemin, Roche). Lymphocytes were isolated by centrifugation on a Ficoll-Triosil gradient (Böyum, 1963) . All centrifugations were carried out at 4°C. Lymphocytes were collected by centrifugation at 400 g for 15 min, and then washed with Hank's medium (medium 199, Grand Island Biological Co., New York). The lymphocyte pellet was sus pended in 2 ml of Hank's medium. Duplicate cell counts were made and the final lymphocyte con centration was adjusted to an average 10 7 cells/ml, 1 -0 ml of the lymphocyte suspension being centrifuged at 400 g for 15 min. The supernatant was discarded and the lymphocyte pellet suspended in 2 ml of the following isotonic medium: potassium dihydrogen phosphate (25 mmol/1) adjusted to pH 7-4 with NaOH solution (2-0 mol/1) and contain ing glutamine (2 mmol/1), glucose (5· 5 mmol/1), sodium chloride (42-2 mmol/1), azaserine (Calbiochem) (1 mmol/1), sodium [ 14 C]formate (0-5 mmol/1; specific radioactivity 6-25 mCi/mmol;The Radiochemical Centre, Amersham, Bucks., U.K.). The lymphocyte suspensions were then incubated at 37°C for 3 h with gentle shaking in a Dubnoff metabolic incubator, after which the tubes were chilled at 4°C to inhibit further reaction. After centrifugation at 900 g for 10 min, supernatants were discarded and lymphocytes washed with 3 ml of cold isotonic sodium chloride solution. Pellets were obtained after centrifugation at 320 g for 10 min and 2-5 ml of perchloric acid (0-52 mol/1) was added to each tube. After centrifugation at 320 g for 10 min, supernatants were collected and pellets washed with 1 ml of perchloric acid (0-52 mol/1). After another centrifugation, the super natants were collected and mixed with the preced ing supernatants and saved for determination of I4 C-labelled 7V-formyl glycinamide ribonucleotide ([ 14 C]FGAR). Pellets were dissolved in 2 ml of NaOH solution (0-48 mol/1) for protein deter mination (Lowry, Rosebrough, Farr & Randall, 1951) , bovine serum albumin (200 mg/1; Sigma, Louis, U.S.A.) being used as standard.
Measurement of l u C]ribonucleotide
Supernatants obtained during the preceding steps were neutralized to pH 7-0 with KOH solution (1 mol/1), stored at 4°C for 30 min, and then centrifuged at 900 g for 15 min. ['"ClFGAR extraction was done according to Henderson (1962) . Neutralized perchloric extracts were poured on columns (10 mm x 35 mm) of Dowex-1 X 8 formate (50-100 mesh). After adsorption, the columns were washed with 50 ml of formic acid (0-5 mol/1). Effluent and washes were discarded. FGAR was then eluted with 32-5 ml of formic acid (4 mol/1). The first 2-5 ml was discarded and six fractions of 5 ml each were collected. A portion (10 ml) of Instagel (Packard) was added to each fraction. The vials were counted for radioactivity in a liquid scintillation counter (SL 40 C|FGAR purity: highvoltage electrophoresis was performed with the following buffers: no. 1, sodium citrate (50 mmol/l), pH 2-9; no. 2, sodium borate (50 mmol/l)/EDTA (1 mmol/l), pH 8-8. Dried electrophoretic paper was cut into 1 cm sections (shown in abscissae) for radioactivity measurements. Each section was mixed with 10 ml of Instagel. The migration pattern of inosinic acid solution (IMP) on electrophoresis is also indicated. The arrow indicates the start of electrophoresis.
Control of purity of[ u C]ribonucleotide
Descending chromatography and electro phoresis on Whatman no. 1 paper were performed after column chromatography. However, to obtain [ I4 C1FGAR with a higher specific radioactivity we modified the technique described above by using the 1 14 C Iformate with specific radioactivity 50 mCi/ mmol. After column chromatography, the 30 ml of formic acid (4 mol/1) extract was dried and the residue dissolved in 500 μΐ of distilled water, 50 /A being used for each paper chromatography or electrophoresis. Four solvents were used (Fig. 1) . High-voltage electrophoresis (2500 V for 30 min) was performed with two buffers (Fig. 2) . A portion (20 μ\) of a saturated inosinic acid solution was simultaneously electrophoresed. Radioactivity was determined as described above. Results were expressed as mean values ± 1 SEM.
Results
Lymphocyte purification
Contamination by other blood cells was measured in 20 blood samples after isolation by the Ficoll-Triosil technique. The number of lym phocytes was 111 50 ± 1115//A. The contamination was 3495 ± 695 erythrocytes/μΐ, 300 ± 90 polymorphonuclear leucocytes/μΐ and 151 700 + 18 200 thrombocytes/,ul. 
Purity of I u C\ribonucleotide
Only one peak of radioactivity was detected on chromatography with solvents no. 2 and no. 4 (Fig.  1) . The corresponding R F values were 0-39 and 0-38 respectively, differing from those obtained by Kelley & Wyngaarden (1970) with ascending chromatography. On the other hand, on chromato graphy with solvents no. 1 and no. 3 Ä F values were 0-05 and 0-17 respectively, identical with those found by Kelley & Wyngaarden (1970) ; another peak of radioactivity was also seen but this second peak contained less than 9% of the total radioactivity. In the absence of azaserine the same main peaks were found but at a very low level. With high-voltage electrophoresis only one peak was obtained (Fig. 2) . The comparative migration of the labelled material and inosinic acid solution confirmed the results of Kelley & Wyngaarden (1970) . Therefore we considered that more than 90% of the radioactivity measured on eluates obtained by ion-exchange chromatography was [ I4 C1FGAR (as determined by paper chromato graphy with solvents no. 1 and no. 3).
Biosynthesis of [ u C\ribonucleotide
Control subjects. 1' 4 C|FGAR synthesis was proportional to the number of lymphocytes in cubated with azaserine (1 mmol/l)) (Fig. 3) (r = 0-91, P < 0-001). However, it seems that this (Fig. 4) . [ l4 C]FGAR synthesis was proportional to the incubation time (Table 1) in control subjects, in gout and in renal failure with and without allopurinol therapy. A 3 h incubation time was thus selected after checking that more than 85% of the cells were alive by Trypan Blue exclusion. Patients with primary gout. In 13 patients with primary gout without allopurinol therapy (group 2A) ['"ClFGAR biosynthesis was 11750 ± 840 c.p.m./mg of protein, higher than the control value (Fig. 6 ), but did not achieve statistical significance. Seven gouty patients overlap with the control value. In eight of 11 treated patients ['"ClFGAR biosynthesis decreased below the control value. Among the three non-responders two belonged to the same family. 
Correlation between [ H C]ribonucleotide and plasma uric acid
We did not find any correlation between [ 
Discussion
The lymphocyte suspension obtained by Böyum's (1963) technique is contaminated by a significant number of other blood cells, especially thrombocytes, but as human platelets do not synthesize nucleotides de novo (Jerushalmy, Sperling, Pinkhas, Krynska & de Vries, 1974 ) the values of [ 14 C]FGAR radioactivity expressed per mg of protein or per 10 6 lymphocytes are not significantly different (Fig. 3) . We are unable to measure (FGAR) and nucleotides identified as formyl glycinamide ribonucleoside polyphosphates. But most of the radioactivity is found in FGAR (Brockman & Chumley, 1965) . Identical studies in cultured human fibroblasts (Kelley & Wyngaarden, 1970; Rosenbloom, Henderson, Caldwell, Kelley & Seegmiller, 1968) have also shown a maximal incorporation of 14 C in FGAR. We have checked that free [ l4 Clformate and serine were discarded by the Dowex-1 X 8 formate chromatography. Two of the four solvents used for paper chromatography gave the same R F values as those obtained by Kelley & Wyngaarden (1970) . However, with the two ammoniacal solvents, the R ¥ values were different in ascending and descending chromato graphy. Taking into account the migration of inosinic acid, the electrophoretic results were identical with those obtained by these investi gators. The dose-response relationship between [ M C1FGAR synthesis and azaserine concentration also suggests that the main radioactivity peak was [
14 C]FGAR. With azaserine concentrations equal to or higher than 10 mmol/l, the amido-phosphoribosyl transferase (EC.2.4.2.14) is inhibited and [ 14 C]FGAR synthesis inhibited. Reem (1972) showed that the enzymes required for the first two steps of the purine biosynthesis de novo are present in human spleen cells. The presence of at least the two first enzymes in circulating blood lymphocytes is confirmed by our results, in contrast to Scott (1962) , who studied [ 14 C|glycine incorporation into soluble nucleotides and nucleic acids in human leucocytes and con cluded that normal and leukaemic human leuco cytes lacked the enzyme system which catalyses the first and the second steps of purine biosyn thesis de novo. Scott (1962) was also unable to find [ 14 Clformate incorporation into the purines of the nucleic acids extracted from normal mature granulocytes in chronic myelocytic leukaemia, possibly because of the low sensitivity of the tech nique with low specific radioactivity formate, the concentration of which when distributed within the formate pool might decrease to background values. Nevertheless Diamond et al. (1969) and Chang et al. (1974) showed that [ 14 C]glycine is incorporated into leucocyte nucleic acids.
There is little variation in [ 14 C]FGAR bio synthesis in control subjects (Fig. 6) . On the contrary, in patients with primary gout, these values are widely scattered and eight of 11 patients treated with allopurinol were in the control range. On the other hand, [
14 C]FGAR biosynthesis was not modified in renal failure associated with hyperuricaemia.
The incorporation of [ 14 C]glycine into urinary uric acid was not determined in our subjects so we have no evidence that the rate of FGAR synthesis in lymphocytes correlated with the rate of purine synthesis in vivo.
The results in the two families of gouty patients were reasonably homogeneous. The first family included two twin brothers with plasma uric acid concentrations of 0-57 and 0·61 mmol/l respec- Values for the incorporation of glycine into urinary uric acid are indicative rather than definitive measurements of the rates of purine production. No independent quantitative method for assessing purine production is always reliable (Wyngaarden & Kelley, 1972) . The 24 h urinary uric acid value generally represents about twothirds of the turnover in normal man, but in gout this may be a smaller fraction (Seegmiller, Grayzel, Laster & Liddle, 1961) . The glycine-incorporation studies suggest that subjects with primary gout show a spectrum of rates of production of uric acid ranging from values within the normal range to much higher values in patients with hypoxanthine phosphoribosyl transferase (EC 2.4.2.8) deficiency (Wyngaarden & Kelley, 1972 Diamond et al. (1969) , as modified by Chang et al. (1974) .
